Hanlin Gao - Jan 26, 2025 Form 4 Insider Report for Fulgent Genetics, Inc. (FLGT)

Role: Chief Scientific Officer
Signature: /s/ Paul Kim as Attorney-in-Fact
Stock symbol: FLGT
Transactions as of: Jan 26, 2025
Transactions value $: -$22,872
Form type: 4
Date filed: 1/28/2025, 04:28 PM
Previous filing: Dec 4, 2024
Next filing: Feb 3, 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	FLGT	Common Stock	Tax liability	-$22.9K	-1.33K	-0.14%	$17.21	918K	Jan 26, 2025	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units assumed pursuant to the Agreement and Plan of Merger, dated as of November 7, 2022 by and among Fulgent Genetics, Inc., FG Merger Sub, Inc., Fulgent Pharma Holdings, Inc., and the stockholders listed therein. These awards were originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on November 9, 2022.

Content

The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units assumed pursuant to the Agreement and Plan of Merger, dated as of November 7, 2022 by and among Fulgent Genetics, Inc., FG Merger Sub, Inc., Fulgent Pharma Holdings, Inc., and the stockholders listed therein. These awards were originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on November 9, 2022.